Summary:
Florida Pulmonary Research Institute is conducting a study to Evaluate the 24-hour Lung
Function Profile in Subjects with Moderate to Very Severe COPD after treatment with PT003, Open-Label Spiriva® Respimat®,and Placebo.
Qualified Participants Must:
• Be 40 years of age or older
•
Have a diagnosis of COPD
Qualified Participants May Receive:
Compensation for participation and study medication.